Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Recurrence 4Leukemia, Myeloid, Acute 3Leukemia 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Lung Neoplasms 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rubinstein-Taybi Syndrome 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Leukemia, Lymphoid 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Carcinoma, Transitional Cell 1Bronchiolitis Obliterans Syndrome 1Breast Neoplasms 1

Interventions

pembrolizumab 185Gemcitabine 170Paclitaxel 152Carboplatin 137Bevacizumab 128Surveys and Questionnaires 118Cisplatin 115Docetaxel 114Blood Specimen Collection 110Cyclophosphamide 109Exercise 108Nivolumab 99Fluorouracil 90Capecitabine 86Radiotherapy 81Dexamethasone 81Irinotecan 74Standard of Care 69Pemetrexed 68Oxaliplatin 68Drug Therapy 65Leucovorin 64Cetuximab 60Erlotinib Hydrochloride 56atezolizumab 53Sorafenib 53Ipilimumab 51Doxorubicin 50trametinib 47Interviews as Topic 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × mocetinostat × Clear all
NCT00372437 2015-07-01

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Mirati Therapeutics Inc.

Phase 1/2 Completed
47 enrolled
Tumor-Agnostic

Neoplasms

NCT00323934 2015-01-08

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Mirati Therapeutics Inc.

Phase 1 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡